Analysts Issue Forecasts for GlaxoSmithKline plc’s FY2022 Earnings (GSK)
GlaxoSmithKline plc (NYSE:GSK) – Equities research analysts at Jefferies Group issued their FY2022 earnings estimates for GlaxoSmithKline in a research note issued to investors on Tuesday. Jefferies Group analyst J. Holford expects that the pharmaceutical company will post earnings of $3.75 per share for the year.
GlaxoSmithKline (NYSE:GSK) last announced its quarterly earnings data on Wednesday, October 25th. The pharmaceutical company reported $0.85 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.84 by $0.01. GlaxoSmithKline had a net margin of 7.79% and a return on equity of 115.30%.
Several other equities analysts also recently issued reports on GSK. UBS Group reissued a “buy” rating on shares of GlaxoSmithKline in a research note on Monday. Zacks Investment Research downgraded shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research note on Wednesday. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a research note on Thursday, September 21st. ValuEngine downgraded shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research note on Sunday, December 31st. Finally, Barclays raised shares of GlaxoSmithKline from an “equal weight” rating to an “overweight” rating in a research note on Tuesday. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and six have issued a buy rating to the company. GlaxoSmithKline presently has an average rating of “Hold” and an average price target of $38.57.
Shares of GlaxoSmithKline (GSK) traded up $0.03 on Wednesday, hitting $38.20. 3,478,233 shares of the company traded hands, compared to its average volume of 5,510,000. The company has a quick ratio of 0.44, a current ratio of 0.64 and a debt-to-equity ratio of 2.96. The stock has a market capitalization of $93,270.00, a P/E ratio of 28.94, a price-to-earnings-growth ratio of 2.36 and a beta of 0.97. GlaxoSmithKline has a fifty-two week low of $34.52 and a fifty-two week high of $44.53.
The business also recently declared a quarterly dividend, which was paid on Thursday, January 11th. Shareholders of record on Friday, November 10th were paid a dividend of $0.5037 per share. The ex-dividend date was Thursday, November 9th. This represents a $2.01 dividend on an annualized basis and a yield of 5.27%. This is an increase from GlaxoSmithKline’s previous quarterly dividend of $0.49. GlaxoSmithKline’s dividend payout ratio (DPR) is currently 154.55%.
In related news, major shareholder Plc Glaxosmithkline purchased 428,571 shares of the business’s stock in a transaction on Monday, November 6th. The shares were bought at an average price of $14.00 per share, with a total value of $5,999,994.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 10.00% of the company’s stock.
A number of large investors have recently bought and sold shares of GSK. FMR LLC increased its position in shares of GlaxoSmithKline by 5.9% in the second quarter. FMR LLC now owns 25,024,276 shares of the pharmaceutical company’s stock worth $1,079,047,000 after acquiring an additional 1,389,238 shares in the last quarter. Fisher Asset Management LLC increased its position in shares of GlaxoSmithKline by 2.3% in the third quarter. Fisher Asset Management LLC now owns 12,828,251 shares of the pharmaceutical company’s stock worth $520,827,000 after acquiring an additional 293,866 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of GlaxoSmithKline by 112.1% in the second quarter. Renaissance Technologies LLC now owns 9,338,000 shares of the pharmaceutical company’s stock worth $402,655,000 after acquiring an additional 4,935,900 shares in the last quarter. Hotchkis & Wiley Capital Management LLC increased its position in shares of GlaxoSmithKline by 7.3% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 8,416,927 shares of the pharmaceutical company’s stock worth $341,727,000 after acquiring an additional 569,600 shares in the last quarter. Finally, Northern Trust Corp increased its position in shares of GlaxoSmithKline by 2.9% in the second quarter. Northern Trust Corp now owns 3,078,478 shares of the pharmaceutical company’s stock worth $132,743,000 after acquiring an additional 85,830 shares in the last quarter. 9.80% of the stock is currently owned by institutional investors.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.